Nearsightedness
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bausch + LombNJ - Bridgewater
1 programExperimental: Myopic defocus soft lens designN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SydnexisSYD-101 0.01%
Bausch + LombExperimental: Myopic defocus soft lens design
Clinical Trials (2)
Total enrollment: 25 patients across 2 trials
The Safety and Efficacy of SYD-101 in Children With Myopia
Start: Apr 2019Est. completion: May 2025
Phase 3Completed
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
Start: Jun 2024Est. completion: Mar 202525 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space